Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 3/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3686010 | 1.00 | L3MBTL1 (0.43) | L3MBTL1PTGS2TP53MAPTKMT2A | |
| SCHEMBL3684612 | 1.00 | L3MBTL1 (0.43) | L3MBTL1PTGS2TP53MAPTKMT2A | |
| SCHEMBL3694201 | 0.93 | CMA1 (0.38) | L3MBTL1PTGS2KMT2ACMA1 | |
| SCHEMBL3685767 | 0.90 | POLB (0.42) | L3MBTL1TP53MAPTKMT2ACMA1 | |
| SCHEMBL3688934 | 0.90 | POLB (0.42) | L3MBTL1TP53MAPTKMT2ACMA1 | |
| SCHEMBL3688507 | 0.90 | POLB (0.42) | L3MBTL1TP53MAPTKMT2ACMA1 | |
| SCHEMBL3686145 | 0.89 | NPC1 (0.34) | L3MBTL1TP53MAPTKMT2A | |
| SCHEMBL3688102 | 0.89 | NPC1 (0.34) | L3MBTL1TP53MAPTKMT2A | |
| SCHEMBL3686142 | 0.89 | NPC1 (0.34) | L3MBTL1TP53MAPTKMT2A | |
| SCHEMBL3685602 | 0.86 | CMA1 (0.39) | L3MBTL1KMT2ACMA1PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188277-B1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-11-21 | — | — | EP | claimed |
| EP-2188277-A1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | claimed |
| WO-2009023655-A1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| US-8377949-B2 | Quinazolinedione chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-19 | — | — | US | disclosed |
| EP-2188277-B1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20120122863-A1 | Quinazolinedione Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| EP-2188277-A1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009023655-A1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122863-A1 | Quinazolinedione Chymase Inhibitors | CMA1, CTSC, TPSG1 | L3MBTL1 4042/4885PTGS2 1440/4885TP53 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.